Avalo Therapeutics, Inc.
AVTX
$18.79
$1.8210.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -6.29% | 80.31% | |||
| Gross Profit | 6.29% | -80.31% | |||
| SG&A Expenses | 6.39% | -5.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.61% | 31.68% | |||
| Operating Income | 0.61% | -31.68% | |||
| Income Before Tax | -47.54% | -57.90% | |||
| Income Tax Expenses | -31.25% | 100.00% | |||
| Earnings from Continuing Operations | -47.48% | -57.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -47.48% | -57.92% | |||
| EBIT | 0.61% | -31.68% | |||
| EBITDA | 0.22% | -31.98% | |||
| EPS Basic | -14.08% | -53.33% | |||
| Normalized Basic EPS | -14.13% | -53.31% | |||
| EPS Diluted | -14.06% | -53.54% | |||
| Normalized Diluted EPS | -14.13% | -53.31% | |||
| Average Basic Shares Outstanding | 29.28% | 2.99% | |||
| Average Diluted Shares Outstanding | 29.28% | 2.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||